Clinical Trial

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-10-24; most recent amendment 2026-03-31.
Status change: Not Yet Recruiting → Recruiting 2024-12-17
Trial Details
NCT Number NCT06660368
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: AbbVie
Conditions Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment 52 participants
Start Date 2024-11-26
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-04-01